Helping individual cancer patients get the right treatment
Posters Presented in 2025
-
![]()
Clinically validated multigene signature predicts taxane benefit in advanced breast cancer. Our machine-learning assay outputs a Drug Sensitivity Score from FFPE tissue to guide docetaxel/paclitaxel use. Presented at ESMO 2025.
-
![]()
Clinically validated multigene signature predicts taxane benefit in early-stage breast cancer. Our machine-learning model, trained on cell-line and patient RNA profiles, reliably stratifies pCR likelihood across multiple cohorts. Presented at ESMO 2025.
-
![]()
An AI-driven gene signature predicting taxane benefit in early-stage breast cancer. AIDA’s 113-gene model accurately stratifies response to neoadjuvant T-AC therapy in I-SPY2 cohorts, outperforming existing biomarkers. Presented at San Antonio Breast Symposium.
Transforming the standard of care
Each year, c. 20 million cancer patients will be newly diagnosed with cancer, and around half will be prescribed drugs to treat their disease. Unfortunately, around 75% of all such treatments do not lead to a positive response, meaning that for many patients their cancer will continue to progress (whilst they potentially suffer from treatment side effects). This is above all bad for the patient but is also demotivating for clinical staff and expensive for healthcare providers – with money wasted on ineffective drugs and the treatment of unnecessary side-effects.
OncoTect®
Every tumor is unique and its treatment should be too.
At AIDA, we analyze RNA expression from a single biopsy to predict how a patient’s tumor will respond to chemotherapy.
Our OncoTect® predicting technology delivers personalized scores to help clinicians select the most effective medical treatment, improving outcomes, and avoiding unnecessary toxicity.
While our technology is built to scale across most cancer therapies, we’re starting with a focus on breast cancer.
Precision that makes a difference.
Empowers Treatment Confidence
We enhance clinical expertise with RNA-based, patient-specific insights beyond standard treatments, enabling faster informed decisions. It integrates seamlessly into workflows, supporting clinicians and promoting patient well-being.
Improves patient outcomes
Patients get the most effective treatment the first time based on their biology and tumor, increasing response rates, reducing harm and saving critical time.
Optimizing Treatment Efficiency
Our technology supports value-based treatment by enabling efficient decisions that reduce waste and costs from ineffective therapies, shorten hospital stays, and minimize repeat interventions.
Redefining Oncology
Our mission is to maximize impact and minimize harm by increasing effective treatment and eliminating ineffective treatments for cancer patients.
We believe the future of oncology lies in precision-guided medicine, matching each patient’s unique genetics and tumor expression to the treatment most likely to help them.
We are ambitious. Our goal is to improve cure rates and double current response rates, improving outcomes for the most widely used cancer drugs, giving more people a real chance at recovery.
Built to Lead. Designed to Scale.
AIDA is transforming cancer treatment.
-
The €38B total addressable market in oncology drug selection is driven by increasing cancer prevalence and a growing demand for personalized treatment approaches. With millions of patients undergoing chemotherapy each year, there is a critical need for tools that help clinicians confidently select the most effective therapies to improve patient outcomes and reduce overall healthcare costs. Our solution is designed to address this vital challenge, positioning us at the forefront of a rapidly expanding market.
-
We are the first to develop predictive tools specifically for the most widely used chemotherapy drugs, addressing a significant unmet need in oncology treatment optimization. No direct competitors currently offer validated solutions targeting this critical area, giving us a unique opportunity to establish strong clinical and commercial leadership. Being first in this space enables us to drive adoption and shape the market standard.
-
Our solution is designed to scale across cancer types, geographies, and partnerships, enabling broad clinical and commercial impact. As we expand to include additional chemotherapy agents, the core technology supports growth without requiring redevelopment. This scalability allows us to adapt to different healthcare systems and pursue a wide range of strategic collaborations.
-
Trained and tested on clinical data from thousands of cancer patients, our predictive models demonstrate strong performance in real-world settings. The technology is backed by leading clinicians across Europe and the United States, with ongoing collaborations further strengthening the evidence base and supporting future clinical adoption.
-
Our solution is protected by a robust intellectual property portfolio, including patents, proprietary algorithms, and exclusive access to clinical data and methods. This layered approach safeguards our competitive advantage and supports long-term value creation. Ongoing filings and data partnerships continue to strengthen our position.
Our experienced leadership team brings over 20 years of expertise in developing technologies for analyzing patient biopsies and gene expression. With backgrounds as oncologists and serial entrepreneurs, we combine deep oncology knowledge with a strong track record in venture building and successfully bringing products to market.
Proven Team
Ulla Hald Buhl, CEO
“Cancer is not a single disease - it’s a dynamic, molecularly diverse challenge. We believe that machine learning combined with gene reading can fast forward personalized cancer therapy and improve treatment options for cancer patients.”
